Trial · NCT04304144
Adverse event totals15
The totals the trial posted for each group.
1 to 15 of 15
Download this page as JSON| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | DLT Period (Part A): CAEL-101 500 mg/m^2 | 0 | 4 |
| Total, all-cause mortality | DLT Period (Part A): CAEL-101 750 mg/m^2 | 0 | 3 |
| Total, all-cause mortality | DLT Period (Part A): CAEL-101 1000 mg/m^2 | 0 | 6 |
| Total, all-cause mortality | Overall (Part A): DLT + Continued Treatment Period: CAEL-101 Combined With SoC CyBorD | 1 | 13 |
| Total, all-cause mortality | Continued Treatment Period (Part B): CAEL-101 Combined With SoC CyBorD and Daratumumab | 2 | 12 |
| Total, other adverse events | DLT Period (Part A): CAEL-101 500 mg/m^2 | 4 | 4 |
| Total, other adverse events | DLT Period (Part A): CAEL-101 750 mg/m^2 | 3 | 3 |
| Total, other adverse events | DLT Period (Part A): CAEL-101 1000 mg/m^2 | 6 | 6 |
| Total, other adverse events | Overall (Part A): DLT + Continued Treatment Period: CAEL-101 Combined With SoC CyBorD | 13 | 13 |
| Total, other adverse events | Continued Treatment Period (Part B): CAEL-101 Combined With SoC CyBorD and Daratumumab | 11 | 12 |
| Total, serious adverse events | DLT Period (Part A): CAEL-101 500 mg/m^2 | 0 | 4 |
| Total, serious adverse events | DLT Period (Part A): CAEL-101 750 mg/m^2 | 0 | 3 |
| Total, serious adverse events | DLT Period (Part A): CAEL-101 1000 mg/m^2 | 1 | 6 |
| Total, serious adverse events | Overall (Part A): DLT + Continued Treatment Period: CAEL-101 Combined With SoC CyBorD | 9 | 13 |
| Total, serious adverse events | Continued Treatment Period (Part B): CAEL-101 Combined With SoC CyBorD and Daratumumab | 7 | 12 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04304144/event-totals